drugset / Trial / NCT00570635
A Phase 2 Study of XL820 in Adults With Advanced GIST Resistant to Imatinib and/or Sunitinib
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the clinical benefit of the KIT inhibitor XL820 in subjects with advanced gastrointestinal stromal tumors (GIST) who are resistant to or intolerant of Imatinib and/or Sunitinib.
Timeline
- Start
- 2007-12
- Primary completion
- 2009-05
- Completion
- 2009-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | XL820 | Unknown | 300 mg | Oral |
| Subject | XL820 | Unknown | 800 mg | Oral |